Nora Volkow, Director of the National Institute on Drug Abuse (NIDA) thinks we should be studying kratom – not classifying it as a Schedule I drug. Dr. Volkow points to exciting new basic science that “point toward the potential of this drug [kratom] in pain research as well as the need for further research on the pharmacology of kratom’s constituents, their toxicity and potential value in the treatment of Opioid Use Disorder (OUD)” – -Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA)
American Kratom Association discusses KCPA and provides an update in their most recent webinar. March 2022.
